The BAP is a learned society and registered charity. It promotes research and education in psychopharmacology and related areas, and brings together people in academia, health services, and industry. Formed in 1974, it is the largest such national association in Europe, and the second largest in the world.
Summer Meeting 2017Join us in Harrogate 23rd to 26th July 2017
Antidepressants and SuicideProf Carmine Pariante attended House of Commons Health Select Committee regarding antidepressants and suicide
Metabolic Guidelines ArticleArticle on the recent metabolic guidelines by Peter Haddad, Gavin Reynolds and Stephen Cooper
Dementia Guidelines MeetingClinical Practice with Anti-Dementia Drugs: Updated Guidelines from the BAP, 19th January 2017
Fundamentals Wins BMA AwardFundamentals of Clinical Psychopharmacology wins BMA Medical Book Award in Psychiatry
Fundamentals of Clinical PsychopharmacologyBuy a discounted copy of the new Fundamentals of Clinical Psychopharmacology
Online CPD ResourceRCPsych Online CPD Subscribers get a discount on the BAP Online Resource
New world order: Brexit, drugs and researchLetter to House of Commons Science and Technology Committee
The Ten Secrets of Success in ScienceView Professor Trevor Robbins presenting his top tips
Neuroscience-based Nomenclature (NbN) for JoPJournal of Psychopharmacology chosen to trial new NbN
Benefits of BAP membership include:
- FREE subscription and access to the Journal of Psychopharmacology (published monthly online).
- Reduced registration fees for the annual Summer Meeting.
- Half price subscription to the Online CPD Resource.
- Eligibility for prizes and awards.
- Student bursaries for the BAP Summer Meeting and international conferences.
- Reduced registration fees for selected partner association events.
- 50% OFF Royal Society of Biology membership (Read more)
- BAP Newsletter.
- Voting for BAP Officers and Council (full members only).
- Being part of one of the largest national psychopharmacology associations in the world.
|10th April 2017||BNA2017 Festival of Neuroscience||ICC, Birmingham|
|11th April 2017||Microglia, neuroinflammation and psychiatric disease: biomarkers and therapeutic potential||ICC, Birmingham|
|26th April 2017||Day A: Schizophrenia / Substance Misuse||Hallam Conference Centre, 44 Hallam Street, London|
From the House of Commons to the Daily Mail, but with the same message: antidepressants save lives
By Carmine Pariante
Posted on 8th March 2017
Antidepressants are always in the news, but the messages coming across are often contradictory. In most countries the use of antidepressants has increased since the year 2000 (although so has the use of anti-hypertension and anti-diabetes medications), yet worldwide less than a fourth of people with depression receive adequate treatment. Some patients are coming forward […]
Genetic insights into psychiatric disorders
By Simon Trent
Posted on 5th March 2017
Psychiatric disorders such as schizophrenia, autism spectrum disorders (ASD) and major mood disorders are common, with 1 in 100 people affected by schizophrenia and a lifetime prevalence of 10% for major depressive disorder. They are highly debilitating to the patient and have a profound impact on the patient’s family, as well as society in general. […]
Is Cannabidiol a useful drug for treating addictions?
By Chandni Hindocha
Posted on 5th March 2017
Anecdotal evidence suggests that people are using Cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, to help them quit smoking cigarettes as well as other drugs. At the same time, emerging research suggests that CBD indeed might be a novel treatment to treat addictions. However, the research itself is sparse and we do not have […]
Can we make cannabis safer?
Tom and co-author Amir talk to Editor Niall Boyce about cannabis harm reduction
1st March 2017
The Emotional Brain: The 14th Oxford Brain Day
Ciara speaks about her work on depression and antidepressants treatments for Oxford Brain Day
25th February 2017
Antidepressants may not be perfect, but they DO save lives
Carmine writes for the Daily Mail showing how, when used correctly, antidepressants do work
21st February 2017
Unexpected deaths of mental health patients in Dorset up 50% in three years
Andrew is interviewed by Bournemouth Echo about increases in unexpected deaths related to mental health
16th February 2017
Why schizophrenia need not rob us of a life in academia
Stephen is interviewed by the Guardian regarding working in academia with a mental illness
1st February 2017
|Anti-Dementia Drugs Guidelines Updated |
20th January 2017
The third revision of BAP Guidelines, 'Clinical practice with anti-dementia drugs', are now available for download.
|ACMD report on Diversion and Illicit Supply of Medicines |
19th December 2016
BAP contributed evidence to the ACMD – Diversion & Illicit Supply of Medicines Inquiry
View letter and report
|British Medical Association (BMA) Research Grants 2017 |
16th December 2016
Applications are open 5th December from medical doctors or research scientists working in the UK for BMA research grants.
|Professor David Nutt receives honorary degree from Bath University |
8th December 2016
BAP warmly congratulates Professor David Nutt, who has been awarded Degree of Doctor of Laws, honoris causa, from Bath University.
Most recent articles:
Journal of Psychopharmacology, Volume 31, Issue 4, Page 397-405, April 2017.
Journal of Psychopharmacology, Volume 31, Issue 4, Page 406-417, April 2017.
Journal of Psychopharmacology, Volume 31, Issue 4, Page 418-433, April 2017.
Psychopharmacology is the study of drugs that affect mood, behaviour and cognition. It aims to develop our understanding of the actions and effects of such drugs, which may include treatments for psychiatric disorders as well as substances that can be abused.